Criteria of the systemic inflammatory response syndrome (SIRS) are known to include patients without systemic inflammation. Our aim was to explore additional markers of inflammation that would distinguish SIRS patients with systemic inflammation from patients without inflammation. The study included 100 acutely ill patients with SIRS. Peripheral blood neutrophil and monocyte CD11b expression, serum interleukin-6, interleukin-1β, tumour necrosis factor-α and C-reactive protein were determined, and severity of inflammation was evaluated by systemic inflammation composite score based on CD11b expression, C-reactive protein and cytokine levels. Levels of CD11b expression, C-reactive protein and interleukin-6 were higher in sepsis patients than in SIRS patients who met two criteria (SIRS2 group) or three criteria of SIRS (SIRS3 group). The systemic inflammation composite score of SIRS2 patients (median 1.5 ; range 0-8, n l 56) was lower than that of SIRS3 patients (3.5 ; range 0-9, n l 14, P l 0.013) and that of sepsis patients (5.0 ; range 3-10, n l 19, P 0.001). The systemic inflammation composite score was 0 in 13/94 patients. In 81 patients in whom systemic inflammation composite scores exceeded 1, interleukin-6 was increased in 64 (79.0 %), C-reactive protein in 59 (72.8 %) and CD11b in 50 (61.7 %). None of these markers, when used alone, identified all patients but at least one marker was positive in each patient. Quantifying phagocyte CD11b expression and serum interleukin-6 and C-reactive protein concurrently provides a means to discriminate SIRS patients with systemic inflammation from patients without systemic inflammation.
INTRODUCTION
The systemic inflammatory response syndrome (SIRS) denotes the host's reaction to inflammatory stimuli of a diverse nature such as infection, trauma, burns, haem-The SIRS criteria were developed, among other reasons, to improve the detection of sepsis in individual patients in general [1] . However, as initially pointed out [1] and later on repeatedly emphasized [9] [10] [11] , the criteria are so sensitive that when used alone they will include patients who virtually lack systemic inflammation. This poor specificity hampers the use of the SIRS criteria in the evaluation of an acutely ill patient.
The purpose of the present study was to explore additional markers of inflammation that would distinguish SIRS patients with systemic inflammation from SIRS patients with little or no systemic inflammation. As markers of systemic inflammation, we measured serum levels of pro-inflammatory cytokines including tumour necrosis factor-α (TNF) [12] , interleukin (IL)-1β [13] and IL-6 [14] , C-reactive protein (CRP), an acute phase reactant [15] , and cell surface expression of an adhesion molecule, CD11b, on peripheral blood neutrophils and monocytes, which increases upon phagocyte activation [16] [17] [18] [19] [20] [21] . On the basis of these markers, we calculated the systemic inflammation composite score (SICS) to evaluate the severity of inflammation in individual patients with SIRS.
PATIENTS AND METHODS

Patient selection and classification
The protocol was approved by the institutional review board. All subjects gave their informed consent to participation. The criteria of SIRS, sepsis, severe sepsis and septic shock were according to the recommendations of the ACCP\SCCM Consensus Conference Committee [1] . The clinical manifestation of SIRS included two or more of the following criteria : a body temperature 38 mC or 36 mC ; a heart rate 90 beats\min ; tachypnoea with a respiratory rate 20 breaths\min, or hyperventilation, as indicated by a PaCO # 32 mmHg ; and an alteration in the leucocyte count, such as 12i10*\l or 4i10*\l, or the presence of more than 10 % immature band forms. Sepsis is SIRS associated with a documented infection. Severe sepsis is sepsis associated with hypotension (a systolic blood pressure 90 mmHg or a reduction of 40 mmHg from baseline in the absence of other causes of hypotension), hypoperfusion or organ dysfunction. Septic shock is hypotension despite adequate fluid resuscitation with the presence of organ perfusion abnormalities.
One hundred patients who met two or more criteria of SIRS were enrolled in the study within 24 h of admission to Helsinki University Central Hospital during a 6-month period. The patients were recruited by one of the investigators from among all those admitted to the medical emergency unit and subsequently hospitalized in an adjoining observation ward. The ward is for temporary observation of the patients who will be either discharged from the hospital or transferred to other wards or units within 48 h. Surgical and unconscious patients were excluded. Parallel blood samples were collected from the SIRS patients and from a healthy adult volunteer (control) representing 36 different volunteers from the hospital staff without medication and with no signs of infection. A total of 50 of such experiments was carried out.
The main reason for hospitalization, medication and survival was assessed from the medical records. Pneumonia was verified by radiological examination of the chest, urinary tract infection by clinical symptoms with compatible findings in urinalysis, and erysipelas by clinical picture. In one patient, blood culture was positive for Enterobacter cloacae. Without regard to the reason for hospitalization, the patient with proven infectious focus was allocated to the sepsis group. Finally, the patients who met 2, 3 or 4 criteria of SIRS, but did not meet the criteria of sepsis, severe sepsis or septic shock, were allocated into groups named SIRS2, SIRS3 and SIRS4 respectively.
Blood samples
Two blood samples were collected from each subject by venepuncture. One sample was taken into a pre-chilled polystyrene tube (Falcon No. 2058, Becton Dickinson Labware, Lincoln Park, N.J., U.S.A.) supplemented with 500 µlofpyrogen-freecitrate(113 mmol\l ;BaxterHealthcare Ltd, Norfolk, U.K.) and 300 µl of dextran (70 kDa, 60 g in 1 litre of physiological saline ; Kabi Pharmacia, Sweden), and the other into a glass tube (Venoject VT-100PZX, Terumo Europe N.V., Leuven, Belgium). Immediately after sampling, the tubes were pressed into thawing ice (0 mC) to minimize leucocyte activation ex vivo [18] . Serum was separated by centrifugation at 4 mC, and stored in aliquots at k20 mC until use. The polystyrene tube was incubated for 60 min at 0 mC, the leucocyte-rich plasma layer was collected into a prechilled polystyrene tube and again kept at 0 mC until labelling of the cells with monoclonal antibodies (see below).
Flow cytometry
The method of cell labelling for flow cytometry was as described earlier [20, 22] . Briefly, aliquots of leucocyterich plasma were double-labelled by the addition of saturating amounts of CD14-FITC (mouse anti-CD14 IgG2b) and CD11b-PE (mouse anti-CD11b IgG2a) or a corresponding control (mouse anti-keyhole limpet haemocyanin IgG2a-PE) antibody (Becton Dickinson, San Jose, CA, U.S.A.). Contaminating erythrocytes were lysed by the addition of 1 : 10 diluted ice-cold FACS lysing solution (Becton Dickinson). The leucocytes were collected by centrifugation at 4 mC, washed once in ice-cold PBS and resuspended in 300 µl of saline supplemented with formaldehyde (final concentration 0.5 %). Finally, the cells were stained with LDS-751 (Exciton, Dayton, OH, U.S.A.), a nucleic acid dye [18] .
The FACScan flow cytometer (Becton Dickinson) and LYSYS II software were used for the acquisition and analysis of the data. Two separate data sets, one for neutrophils (5i10$ LDS-751-positive events) and the other for monocytes (1i10$ CD14-positive events), were acquired for each specimen, as described previously [20, 22] . During the analysis, multiple electronic gates were used to identify intact neutrophil and monocyte populations. In a forward\side light-scatter dot plot, LDS-751-positive neutrophils were first separated from contaminating mononuclear cells by creating a region, R1. Next, in an LDS-751 fluorescence\side scatter dot plot, a second region, R2, was created to separate neutrophils from cell aggregates and from damaged cells with markedly increased LDS-751 permeability and fluorescence intensity. Finally, the CD11b expression on intact neutrophils (i.e. on cells co-located in the regions R1 and R2) was evaluated by creating a CD11b histogram. CD14-positive monocytes collected in live mode were similarly analysed. CD11b expression is reported in relative fluorescence units (RFU), i.e. as the median channel of the positively fluorescent cell population. In all experiments, 95 % of neutrophils and monocytes were CD11b positive.
Cytokine and CRP determinations
The ELISA kit for human IL-6 (lowest standard 10 pg\ml, sensitivity 10-15 pg\ml) was purchased from the Central Laboratory of the Netherlands Red Cross, Amsterdam, The Netherlands, and the Predicta2 ELISA kits for human IL-1β (lowest standard 4 pg\ml, sensitivity 3 pg\ml) and TNF (lowest standard 15 pg\ml, sensitivity 10 pg\ml) were from Genzyme Diagnostics, Cambridge, MA, U.S.A. The serum concentration of CRP was measured immunoturbidimetrically (detection limit 2 µg\ml). The reagents were from Orion Diagnostica, Espoo, Finland.
Evaluation of systemic inflammation
To evaluate the severity of systemic inflammation, we used the SICS. To obtain the SICS value for each patient, a subscore between 0 and 4 points was assigned to each marker of systemic inflammation as follows. The subscores for IL-1β, IL-6 and TNF concentrations were as used by Rixen et al. [6] , with some modifications based on the cytokine levels detected in previous studies of patients with sepsis [23] [24] [25] [26] . In the calculation of the SICS for a given patient, only the higher phagocyte CD11b subscore (that of the neutrophils or that of the monocytes) was used. The maximum SICS was 20 (IL-6 level 1000 pg\ml, IL-1β and TNF levels both 300 pg\ml, CRP level 200 µg\ml, and CD11b fluorescence intensity value 200 RFU in either neutrophils or monocytes).
Data analysis
Statistical comparisons between SIRS2 patients, SIRS3 patients, patients with sepsis and healthy subjects were performed using the Kruskal-Wallis analysis of variance and the Mann-Whitney U-test. The significance of the difference in mortality between the groups was evaluated by Fisher's exact test. Probabilities were regarded as statistically significant at the 0.05 level. Results are reported as median values (range).
RESULTS
Patients
The characteristics of the patients are shown in Table 1 . The spectrum of the diagnoses was markedly broad ( Table 2) . Out of a total of 100 patients, 61 met two criteria of SIRS (the SIRS2 group), 14 met three criteria (the SIRS3 group) and two met four criteria (the SIRS4 group). There were 17 patients with drug intoxication, five of whom had concurrent pneumonia and were allocated into the sepsis group. There were 15 patients with acute myocardial infarction (12 in the SIRS2 group and one each in the SIRS3, SIRS4 and sepsis groups). A total of 23 patients met the criteria of sepsis ; two met the criteria of severe sepsis and one of septic shock. A total of 9 patients died ; five in the SIRS2 group (two with cardiogenic shock due to acute myocardial infarction, one with dilating cardiomyopathy, one with abdominal aortic aneurysm and one with breast cancer), two in the SIRS3 group (one with lung cancer and the other with rectal cancer), one in the sepsis group (pneumonia) and one in the septic shock group (adult respiratory distress syndrome and acute renal failure). Twenty-six patients were discharged from the hospital after a surveillance period of less than 48 h. Sixty-nine patients were transferred to medical wards, four patients to an intensive care unit, and one patient died in the observation ward.
CD11b expression on neutrophils and monocytes
The median levels of phagocyte CD11b expression increased with the severity of SIRS and sepsis (Figure 1) . Systemic inflammatory response syndrome 
Serum concentrations of IL-6, CRP, IL-1β and TNF
The median serum levels of IL-6 increased in the order of SIRS2 l SIRS3 sepsis (Figure 2 The CRP levels increased in the order of SIRS2 SIRS3 sepsis (Figure 2) . The levels in the SIRS2 patients Horizontal bar indicates median, and dotted line the assay detection limit. See legend to Figure 1 for comparison of groups.
[8 (0-216) µg\ml] were significantly lower than those in the SIRS3 [85 (0-160) µg\ml] and sepsis patients [151 (6-238) µg\ml]. In the sepsis group, one patient had pneumonia and a history of aspiration 12 h before hospitalization, and another patient had urinary tract infection and onset of fever 6 h before hospitalization. The CRP levels were 6 µg\ml and 22 µg\ml respectively, suggesting an absence of systemic inflammation. However, neutrophil CD11b expression levels were 235 RFU and 99 RFU respectively, and serum IL-6 levels 95 pg\ml and 270 pg\ml respectively, indicating an ongoing systemic reaction. By the next day, the CRP levels had increased to 133 µg\ml and 151 µg\ml respectively.
The serum levels of IL-1β were detectable in 21 patients only, and increased in the order of SIRS2 l SIRS3 sepsis (Figure 2) . TNF was found in the sera of two 
Severity of systemic inflammation
Complete data for calculating SICS were available from 94 patients. SICS increased in the order of SIRS2 SIRS3 sepsis, and the differences between the groups were statistically significant ( Figure 3) . SICS was 3 in 36 patients (38.3 %). Out of these, 34 patients (94.4 %) belonged to the SIRS2 group and the remaining patients to the SIRS3 group. Thus, none of the sepsis patients had SICS 3. The median SICS of the patients who died was 5 (range 2-8, n l 8 ; in one case SICS could not be calculated due to missing data).
In 13 patients (13.8 %, 11 patients in the SIRS2 group and two in the SIRS3 group) SICS was 0, indicating an absence of systemic inflammation. Out of 70 SIRS2 and SIRS3 patients, 24 (34.3 %) had a SICS between 3 and 9, suggesting that the degree of systemic inflammation was similar to that of the sepsis patients. Five of the 24 patients with a SICS 3 died, whereas only one of the 46 patients with SICS 3 died (P l 0.016, Fisher exact test). In the SIRS2 group, the highest SICS values, 7 and 8 respectively, were seen in two patients, one with large, acute myocardial infarction complicated by alveolar oedema, and the other with exacerbation of Crohn's disease. In the SIRS3 group, two patients had a SICS of 7, one with drug intoxication and the other with malignant pericardial effusion. The patient with the SICS value of 9 in the SIRS3 group later on proved to be suffering from nephropathia epidemica, a European form of haemorrhagic fever with renal syndrome caused by Puumala hantavirus [29] . Of the two patients in the SIRS4 group, one (SICS l 5) had acute myocardial infarction and the other suffered from alcohol intoxication.
Markers that identify patients with systemic inflammation
A total of 81 patients had a SICS 1. IL-6 was increased in 64 (79.0 %), CRP in 59 (72.8 %), CD11b expression in 50 (61.7 %), IL-1β in 21 (25.9 %) and TNF in 2 (2.5 %). Thus, none of the markers, if used alone, identified all patients. Of the 81 patients, 92.6 % had increased levels of either CRP or IL-6, or both, 86.4 % had increased levels of either CRP or CD11b expression, or both, and 92.6 % had increased levels of either IL-6 or CD11b expression, or both. At least one marker (IL-6, CRP or CD11b expression) was increased in each of the 81 patients.
DISCUSSION
The clinical criteria of SIRS are commonly considered to be so sensitive that they are probably able to include all patients with ongoing systemic inflammation. However, the criteria are not very specific [1, [9] [10] [11] , and therefore, when used alone, may not facilitate recognition of an acutely ill individual patient with systemic inflammation. The results in the present study show that 13.8 % of acutely ill patients had a SICS of 0. They belonged to the SIRS2 or SIRS3 group. In other words, despite the fact that these patients met two or three SIRS criteria, there was no evidence of ongoing systemic inflammation, as determined by the levels of circulating IL-6, CRP, IL-1β and TNF, and by the CD11b expression on peripheral blood neutrophils and\or monocytes. On the other hand, 34.3 % of the patients in the same SIRS groups had a SICS as high as that of the patients with sepsis. The present results agree with recent findings demonstrating a lack of correlation between the severity of SIRS and plasma proinflammatory cytokine levels in patients with acute respiratory distress syndrome [7] , and confirm that the clinical criteria of SIRS do not reliably discriminate between patients with and without systemic inflammation. However, because inflammation is a dynamic process involving sequential activation of humoral and cellular host-defence mechanisms, a crucial question is whether the markers of inflammation used in the present study are sensitive enough to detect systemic inflammation at its different stages. Several lines of evidence suggest that this is the case.
First, the increase in CD11b\CD18 expression may serve as an extremely early and sensitive cell-associated marker of phagocyte activation because it does not require time-consuming de novo protein synthesis [30] , can be verified in a small subpopulation of cells [31] and occurs in vivo within minutes in response to the stimulus [32] . It also occurs in several SIRS-triggering disorders like sepsis [18, 19, 33] , haemodialysis [21] , whole-body trauma [34] , burn injury [35] and cardiac surgery [20, 32, 36] . Secondly, the induction of TNF, IL-1β, and IL-6 production occurs sequentially within hours in response to the insult [37] . Together, these pro-inflammatory cytokines and phagocyte CD11b expression should provide early humoral and cell-associated markers of systemic inflammation. However, the present study design should also cover later stages of systemic inflammation. The CRP concentration peaks 24 to 48 h after the onset of the fever [38] . This, and the finding that an increase in the IL-6 level precedes increases in the CRP level in patients with infection [39] , indicates that circulating CRP serves as a delayed marker of systemic inflammation. In keeping with this assumption, we recorded in two patients an increase in IL-6 and CD11b expression levels before a CRP elevation. In concert, the present findings strongly suggest that circulating IL-6 and CRP levels and surface expression of CD11b, quantified concurrently, provide reasonably reliable means to identify acutely ill patients who present with systemic inflammation at its different stages.
TNF was found in only two patients in the present study. TNF has a median elimination half-life as short as 17 min [40] and its concentrations can change substantially within hours [41] . Therefore, in clinical studies transient elevations of circulating TNF are easily missed. This can explain at least partially the wide variation in results of 15 studies indicating that immunoreactive TNF occurs in 16-100 % of patients (for references, see [42] ). The detectable levels of IL-1β in patients with severe infections are also variable [42] . Casey et al. [24] found IL-1β in 37 % of patients (n l 97) with sepsis syndrome. In the present study, IL-1β was found in 21 % of the patients. Together, these findings suggest that TNF and IL-1β are not particularly sensitive markers of systemic inflammation in the patients with SIRS.
To characterize the systemic inflammation status of an individual patient, we calculated for each patient a SICS, i.e. the sum of the subscore values determined by the levels of cytokines, CRP and CD11b expression. The limits for maximum subscore value (equal to 4) and minimum subscore value (equal to 0) for cytokines and CRP were set according to the results of previous studies carried out by us [26] and others [23] [24] [25] 27, 28] . Respective limits for CD11b expression were set with regard to our previous studies of patients with sepsis\ septic shock [26] and to the current study of healthy subjects ( Figure 1) . Next, the limits for the subscores 1-3 were set arbitrarily. Because the cut-off points were selected by exploiting the results of sepsis studies, but in the present study only a minority of the patients had sepsis, we also tested other cut-off points, especially for IL-6 and CRP, but did not achieve any better separation between SIRS groups and the sepsis group.
Our results show that each patient in the sepsis group had a SICS 3. However, the high SICS values were not exclusively associated with sepsis. Furthermore, it was difficult to exclude with certainty the presence of an infectious focus in some patients with a high SICS. This is exemplified in our patient with myocardial infarction complicated by alveolar oedema in whom the signs of systemic inflammatory response may have derived from either heart tissue injury [43] or concurrent pneumonia, or from both. Taken together, the results suggest that if the SICS is low, an acutely ill patient who meets the SIRS criteria most probably does not have sepsis whereas if the SICS is high, the patient should be carefully examined for the presence of infection, among other disorders able to elicit the systemic inflammatory reaction.
In conclusion, the results show that it is possible to distinguish SIRS patients with and without systemic inflammation by quantifying concurrently phagocyte CD11b expression and circulating IL-6 and CRP levels. These additional markers make it possible to take advantage of the great sensitivity of the SIRS criteria when evaluating acutely ill individual patients in general.
